Four SNPs, T253C, C489T, G835A and G853A were genotyped by a homogeneous mass extension assay at the Australian Genome Research Facility (St Lucia, Queensland).
Six non-synonomous SNPs in P2RX7 with functional consequences for the receptor were analysed in 506 samples by a homogeneous mass extension assay (HME) at the Australian Genome Research Facility (St Lucia, Queensland, Australia).
Homogeneous mass extension (hME, Sequenom) genotyping was performed on a panel of patients to rapidly screen for the presence of the novel SNVs.
Large congenital tumors may cause compression of vital structures or cardiovascular complications, and in these cases, MRI is the method of choice to determine the mass extension and its relationship to the adjacent anatomical structures (Fig. 3c, d).
This is based on existing formats of satellite designed to fly above the usual altitude floor (500 km) and therefore according to limited mass extension (∼10%) to accommodate the extra ΔV and propulsion needs for flying lower than usual.
Polymerase chain reactions, treatment of PCR products with alkaline phosphatase, and mass extension reactions were all performed according to the manufacturer's protocol (Sequenom).
P2RX7 genotyping was performed by homogeneous mass extension.
All primers in the PCR and homogenous mass extension reactions were designed using Assay Designer 3.1 (Sequenom, Inc).
Genotyping was done with homogeneous mass extension using the MassARRAY System (Sequenom, San Diego, California) in multiplexes of two to six SNPs.
Brain MRI at that time showed interval development of new diffuse osseous metastatic disease in the skull, not present at the time of radium, with intracranial and intraorbital mass extension, exerting mass effect on the lateral rectus and optic nerve.
